Delivery Order SPE2DB24D1021-SPE2DB25FEYZM
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,066.95 by the Defense Logistics Agency (DLA) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. The contract covers the supply of Actemra ActPen 162 mg/0.9 mL injections and was awarded through competitive bidding without set-aside designation under a firm fixed-price arrangement. This delivery order operates as a child...
- The Defense Logistics Agency awarded a delivery order valued at $3,529.18 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 200 mg/10 mL vials on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant used in treating rheumatoid...
- The Defense Logistics Agency (DLA) awarded a $7,362.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 162 mg/0.9 mL Actemra syringes on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, fulfilled this delivery order under its...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 26, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes valued at $5,945.97 with a firm fixed price structure. The contract specifies a completion date of July 28, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This is an unrestricted, competitively awarded delivery order with no set-aside designation. This delivery order is...
- This is a $13,939.20 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication, with a completion date of July 10, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a...
- The Defense Logistics Agency (DLA) Troop Support Medical has awarded a $1,503.76 firm fixed price delivery order to Amerisourcebergen Drug Corp for the supply of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty pharmaceutical product. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 and a performance period through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen to deliver pharmaceutical products and...
- This is a $8,458.38 fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide ACTEMRA 162 mg/0.9 mL syringes. The contract has a completion date of July 9, 2025 and is not set aside. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle through December 2026....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- This is a $11,253.24 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a medication used to treat certain autoimmune diseases. The contract has an ultimate completion date of June 25, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00...
- This is a $4,316.76 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty pharmaceutical product, with a period of performance through March 4, 2025. The award was not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEYZMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,755.68 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 162 mg/0.9 mL syringes on July 28, 2025. This competitively awarded, non-set-aside contract employs firm fixed price terms and requires completion by July 29, 2025. The performance location is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. ACTEMRA (tocilizumab) is a biologic immunosuppressant medication used to treat rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen serves military and veteran healthcare systems through its comprehensive IDC vehicle, which enables the supply of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs globally. The DLA Troop Support Medical contract allows flexibility in fulfilling medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 7/28/25 |